TransMedics Group Inc (TMDX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.17B
Last updated: Nov 17, 2026 at 11:06 AM ET
TransMedics Group Inc (TMDX) P/E Ratio & Valuation History
TransMedics Group (TMDX) trades at 70.9x trailing earnings and 4.4x sales. Its P/S of 4.4x is below its 5-year median of 11.0x. Its forward P/E is 31.1x. The median P/E across 9 similar companies is 23.8x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 128.0% higher over the next year. Its free cash flow yield is 1.4%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 70.9x |
| Forward P/E | 31.1x |
| Price to sales | 4.4x |
| Price to book | 5.8x |
| EV/EBITDA | 25.7x |
| Price to FCF | 71.6x |
| EV/FCF | 79.8x |
| PEG | 0.9 |
| FCF yield | 1.4% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 4.4x | 11.0x | N/A |
| P/B | 5.8x | 12.6x | N/A |
Valuation History
Over the 3 of the 7 year ends shown that have a P/E, its P/E ranged from 52.2x in 2025 to 986.6x in 2023.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $121.65 | 52.2x | 7.1x | 10.5x |
| 2024 | $62.35 | 61.7x | 4.8x | 9.6x |
| 2023 | $78.93 | 986.6x | 10.8x | 19.7x |
| 2022 | $61.72 | N/A | 19.7x | 10.5x |
| 2021 | $19.16 | N/A | 17.5x | 7.8x |
| 2020 | $19.90 | N/A | 19.1x | 5.2x |
| 2019 | $19.01 | N/A | 14.6x | 7.4x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TMDX
What is TMDX's forward P/E ratio?
TransMedics Group has a forward P/E ratio of 31.1x.
Is TMDX stock overvalued?
GNG's valuation label for TMDX is Undervalued. Its P/E of 70.9x compares with a median of 23.8x across 9 similar companies.
What is TMDX's price to sales ratio?
TransMedics Group has a price to sales ratio of 4.4x.
What is TMDX's PEG ratio?
TransMedics Group has a PEG ratio of 0.9.
TMDX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors